The company incurred a loss in its most recent quarterly results.
Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...
This healthcare giant is trading at a discounted price today.
Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true.
Barchart on MSN
The best covered call strategy to trade high-yielding Pfizer stock and earn extra income
Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start.
Pfizer offers a 6.3% yield, but its high dividend reflects weak growth prospects and looming patent cliffs. PFE’s dividend is currently covered by cash flow, but payout ratios are stretched, and ...
Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial ...
From a fundamental perspective, Pfizer's shares present a compelling value within the sector. The stock trades at a notable discount to industry peers, with an estimated forward price-to-earnings (P/E ...
Pfizer (NYSE:PFE) received full FDA approval for BRAFTOVI (encorafenib) with cetuximab and fluorouracil-based chemotherapy as a first-line treatment for adults with BRAF V600E-mutant metastatic ...
Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results